Therapeutic | Cemiplimab |
Target | PDCD1 |
Heavy Chain | EVQLLESGGVLVQPGGSLRLSCAASGFTFSNFGMTWVRQAPGKGLEWVSGISGGGRDTYFADSVKGRFTISRDNSKNTLYLQMNSLKGEDTAVYYCVKWGNIYFDYWGQGTLVTVSS |
Light Chain | DIQMTQSPSSLSASVGDSITITCRASLSINTFLNWYQQKPGKAPNLLIYAASSLHGGVPSRFSGSGSGTDFTLTIRTLQPEDFATYYCQQSSNTPFTFGPGTVVDFR |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G4 |
Highest Clinical Trial (June '19) | Approved |
Estimated Status (June '19) | Active |
Recorded Developmental Technology | na |
INN Year Proposed | 2018 |
INN Year Recommended | 2019 |
Companies Involved | Inovio Pharmaceuticals, ISA Pharmaceuticals, Regeneron Pharmaceuticals, Sanofi, Sidney Kimmel Cancer Center, SillaJen Biotherapeutics, University of Texas M. D. Anderson Cancer Center |
Conditions Approved | Squamous cell cancer |
Conditions Active | Cervical cancer, Non-small cell lung cancer, Basal cell cancer, Oropharyngeal cancer, Prostate cancer, Fallopian tube cancer, Glioblastoma, Multiple myeloma, Ovarian cancer, Peritoneal cancer, Solid tumours, B-cell lymphoma, Cancer, Head and neck cancer, Malignant melanoma, Renal cell carcinoma |
Conditions Discontinued | na |
Notes |